Pharvaris, a biopharmaceutical company, will be presenting six abstracts at the AAAAI 2026 Annual Meeting. The abstracts cover data on deucrictibant for HAE and AAE-C1INH treatment. The company aims to share positive study results and present data from past studies at the meeting in Philadelphia from February 27-March 2, 2026. The data includes efficacy and safety results from previous studies, as well as on-demand endpoint validation findings. Pharvaris is working on global marketing authorization applications for deucrictibant as a treatment for HAE attacks and is conducting a pivotal Phase 3 study for long-term prophylaxis.

Read more at GlobeNewswire: Pharvaris to Present Clinical Data at the AAAAI 2026 Annual